Patients with high-risk multiple myeloma (HRMM) represent a subgroup of 15–20% of MM patients and have reduced survival rates.1,2 The current classification of HRMM includes the presence of at least one mutation associated with poor prognosis, such as del(17p), t(4;14), or t(14;16), and was extended to include 1q21+ in the second revision of the Revised International Staging System.3,4 In recent years, new diagnostic and prognostic factors have emerged, making the HRMM disease profile even more complex.5,6 As the prevalence of MM continues to increase globally, and the disease is still incurable, extensive research is being conducted to improve current treatment strategies.7 One potential improvement is the addition of anti-CD38 antibodies, such as isatuximab or daratumumab, to existing treatment regimens. At EHA 2023, Prof. Dr. Thierry Facon (Lille University Hospital, France) presented the long-term results of isatuximab in combination with carfilzomib-dexamethasone (Isa-Kd) in patients with 1q21+ status.8 Prof. Dr. Philippe Moreau (University Hospital of Nantes, France) discussed the results of Isa-Kd and isatuximab in combination with pomalidomide-dexamethasone (Isa-Pd) in MM patients with an ultra-high-risk profile.9 In addition, new data demonstrated that isatuximab with weekly Kd can be used as an appropriate and more convenient salvage regimen in patients with relapsed and/or refractory multiple myeloma (RRMM).10